1. Home
  2. AUPH vs ALMR Comparison

AUPH vs ALMR Comparison

Compare AUPH & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$14.88

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Alamar Biosciences Inc. Common Stock

ALMR

Alamar Biosciences Inc. Common Stock

N/A

Current Price

$28.64

Market Cap

2.1B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
AUPH
ALMR
Founded
1993
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
AUPH
ALMR
Price
$14.88
$28.64
Analyst Decision
Buy
Buy
Analyst Count
6
5
Target Price
$18.50
★ $37.00
AVG Volume (30 Days)
★ 819.4K
674.6K
Earning Date
10-30-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.76
N/A
Revenue
★ $283,055,000.00
N/A
Revenue This Year
$16.65
$64.80
Revenue Next Year
$17.73
$37.27
P/E Ratio
$19.89
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.52
$21.58
52 Week High
$19.25
$39.61

Technical Indicators

Market Signals
Indicator
AUPH
ALMR
Relative Strength Index (RSI) 32.23 45.59
Support Level $14.76 $23.87
Resistance Level $15.15 $29.06
Average True Range (ATR) 0.53 2.38
MACD -0.19 -0.06
Stochastic Oscillator 4.44 47.77

Price Performance

Historical Comparison
AUPH
ALMR

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About ALMR Alamar Biosciences Inc. Common Stock

Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

Share on Social Networks: